BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36516952)

  • 21. Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311).
    Ishikawa M; Shibata T; Kataoka T; Takekuma M; Kobayashi H; Yaegashi N; Satoh T;
    Int J Gynecol Cancer; 2023 May; 33(5):692-700. PubMed ID: 36997229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer.
    Moon JY; Song IC; Ko YB; Lee HJ
    Medicine (Baltimore); 2018 Apr; 97(14):e0340. PubMed ID: 29620661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
    Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
    Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study.
    Chu G; Liu X; Yu W; Chen M; Dong L
    BMC Cancer; 2021 Feb; 21(1):133. PubMed ID: 33549065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
    Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
    Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topotecan in cervical cancer.
    Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
    Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.
    Machida H; Moeini A; Ciccone MA; Mostofizadeh S; Takiuchi T; Brunette LL; Roman LD; Matsuo K
    Am J Clin Oncol; 2018 Sep; 41(9):851-860. PubMed ID: 28763329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
    Tanigawa T; Takeshima N; Ishikawa H; Nishio S; Usami T; Yamawaki T; Oishi T; Ihira K; Kato H; Goto M; Saito M; Taira Y; Yokoyama M; Shoji T; Kondo E; Mori A; Yokoi T; Iwasa-Inoue N; Hirashima Y; Nagasawa T; Takenaka M; Mikami M; Sugiyama T; Enomoto T
    Gynecol Oncol; 2022 Jun; 165(3):413-419. PubMed ID: 35487773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
    Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
    Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix.
    Choi CH; Kim TJ; Lee SJ; Lee JW; Kim BG; Lee JH; Bae DS
    Int J Gynecol Cancer; 2006; 16(3):1157-64. PubMed ID: 16803500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
    Tinker AV; Fiorino L; O'Dwyer H; Kumar A
    Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
    Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
    Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
    McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
    Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updates and management algorithm for neuroendocrine tumors of the uterine cervix.
    Salvo G; Gonzalez Martin A; Gonzales NR; Frumovitz M
    Int J Gynecol Cancer; 2019 Jul; 29(6):986-995. PubMed ID: 31263021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
    Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.